stockrowCabot Corporation
CBT Basic Materials Specialty Chemicals
Cabot Corporation’s revenue for fiscal 2025 (year ended September 2025) was $3.7 billion, down 7.04% from fiscal 2024.
- Revenue
- +12.2%
- EPS
- +79.4%
- Free cash flow
- −51.7%
- Total debt
- +10.8%
Quarter to September 2026, against a year earlier
Follow CBT
Alert me
Cabot Corporation (CBT) EBITDA
Cabot Corporation's EBITDA for fiscal 2025 was $775.0M, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $673.0M. Over the past ten years it has ranged from $179.0M (fiscal 2020) to $775.0M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. Cabot Corporation ranks 18th of 59 Specialty Chemicals companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $775.0M | 1.31% |
| FY2024 | $765.0M | 14.18% |
| FY2023 | $670.0M | 25.23% |
| FY2022 | $535.0M | (12.87%) |
| FY2021 | $614.0M | 243.02% |
| FY2020 | $179.0M | (60.57%) |
| FY2019 | $454.0M | 17.92% |
| FY2018 | $385.0M | (21.91%) |
| FY2017 | $493.0M | 20.83% |
| FY2016 | $408.0M | 87.16% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $148.0M | (16.85%) |
| Mar 2026 | $178.0M | 4.71% |
| Dec 2025 | $170.0M | (3.95%) |
| Sep 2025 | $177.0M | (14.08%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| CBT Cabot Corporation | $673.0M |
| FUL H. B. Fuller Company compare | $564.5M |
| AVNT Avient Corporation compare | $505.6M |
| ASH Ashland Inc. compare | $336.0M |
| SXT Sensient Technologies Corporation compare | $317.0M |
| PRM Perimeter Solutions, SA compare | $230.0M |
| HWKN Hawkins, Inc. compare | $181.8M |
| CLMT Calumet, Inc. compare | $133.9M |
| WDFC WD-40 Company compare | $119.3M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CBT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement